Protagonist Therapeutics Financial Ratios
NASDAQ: PTGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
143.73+3.82 (+2.73%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Protagonist Therapeutics ratio analysis
Protagonist Therapeutics earned a net margin of -282.8% in FY 2025, down from 63.3% a year earlier. Return on equity reached -21.2%, meaning Protagonist Therapeutics generated -0.21 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Protagonist Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | 9.35 | — | — | — | — | — | — | — | — |
| Price / sales | 120.44 | 5.61 | 21.69 | 20.13 | 57.91 | 24.22 | 738.71 | 5.02 | 18.34 | — |
| Price / book | 9.02 | 3.61 | 3.87 | 2.48 | 5.28 | 2.48 | 2.13 | 1.38 | 3.05 | 1.63 |
| Operating margin | -343.6% | 58.2% | -156.1% | -494.2% | -460.0% | -225.4% | -34,857.6% | -136.7% | -188.9% | — |
| Net margin | -282.8% | 63.3% | -131.6% | -479.3% | -458.9% | -231.1% | -33,414.3% | -125.9% | -184.2% | — |
| Free cash flow margin | 121.9% | 42.1% | -118.1% | -409.8% | -398.3% | -254.8% | -18,395.7% | -163.1% | 16.0% | — |
| Return on equity (ROE) | -21.2% | 40.8% | -23.5% | -59.1% | -41.8% | -23.7% | -96.5% | -34.6% | -30.6% | -42.5% |
| Return on assets (ROA) | -19.5% | 37.0% | -22.1% | -51.4% | -36.1% | -20.4% | -49.8% | -27.9% | -22.6% | -39.6% |
| Debt / equity | — | — | — | — | — | — | 0.12 | — | — | — |
| Current ratio | 12.71 | 12.48 | 16.71 | 7.80 | 7.74 | 7.84 | 4.10 | 5.26 | 3.55 | 12.94 |
| Revenue growth | -89.4% | 624.1% | 125.7% | -2.8% | -4.4% | 12,293.1% | -99.3% | 54.1% | — | — |
| EPS growth | -148.5% | — | — | — | — | — | — | — | — | — |